Coronavirus M Protein Binding Disruption via MYO5B Interaction Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections lack effective methods to disrupt the interaction between coronavirus membrane glycoprotein (M protein) and Myosin Vb protein (MYO5B), which is crucial for viral trafficking and assembly in host cells.
Innovation Solution
Administering an agent that selectively binds to the M protein or MYO5B, such as antibodies, aptamers, small molecules, or soluble fragments of M protein or MYO5B, to inhibit their interaction, thereby disrupting viral trafficking and assembly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no specific agent is used to disrupt M protein and MYO5B interaction, then the viral trafficking and assembly proceed normally, but coronavirus infection cannot be effectively treated or prevented
Solution Approach 1:
The patent employs intermediary molecules (antibodies, aptamers, small molecules, or soluble protein fragments) that bind to either the M protein or MYO5B to disrupt their interaction. These intermediaries act as mediators that prevent the direct binding between viral M protein and host MYO5B, thereby blocking viral trafficking and assembly without requiring direct modification of the virus or host cell machinery.
2Object-affected harmful factors
If an agent is designed to selectively bind M protein or MYO5B to disrupt their interaction, then viral trafficking is blocked, but the specificity and selectivity of the agent must be maintained to avoid off-target effects
Solution Approach 1:
The patent focuses on targeting specific local regions (binding sites) of either the M protein or MYO5B rather than the entire protein structure. By designing agents that selectively bind to specific epitopes or domains involved in the M-MYO5B interaction, the patent achieves localized disruption of viral trafficking while maintaining selectivity and minimizing off-target effects on other cellular processes.
3Reliability
If soluble fragments of M protein or MYO5B are used as therapeutic agents, then the interaction is disrupted with potentially high specificity, but the complexity of identifying and producing the correct fragment increases
Solution Approach 1:
The patent employs segmentation by using soluble fragments of either M protein or MYO5B as therapeutic agents. Instead of using full-length proteins, the invention divides the protein structures into smaller functional segments (fragments or domains) that retain the ability to bind the target protein and disrupt the interaction. This segmentation reduces molecular weight, improves solubility, and may enhance tissue penetration while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed method effectively prevents coronavirus infection by disrupting the critical interaction between M protein and MYO5B, potentially offering a therapeutic approach to treat or prevent coronavirus infections.
Implementation Method 1
an agent that selectively binds M protein at or near its MYO5B binding site, or selectively binds MYO5B at or near its M protein binding site
Data Source
AI summary
Disclosed herein is a method for treating or preventing a coronavirus infection in a subject that involves administering to the subject an effective amount of a composition comprising an agent that disrupts the binding of coronavirus membrane glycoprotein (M protein) and Myosin Vb protein (MYO5B). Also disclosed herein is a method for identifying an agent for treating or preventing a coronavirus infection that involves providing a system comprising coronavirus membrane glycoprotein (M protein) and human Myosin Vb protein (MYO5B) with conditions suitable for binding of the M protein and MYO5B; contacting the system with a candidate agent; and assaying the system for binding of M protein and MYO5B.